Snowball logo
logo
BIM_logo

Biomerieux SA

73.000.00  (0%)
Estimate
P/E
18.7
EPS
3.9
Beta
0.57
Growth
Revenue, YoY
-5.46%
Net income, YoY
4.24%
FCF, YoY
533.9%
Forecast
P/E (FWD)
15.6
EPS (FWD)
4.665
Dividends
Dividend yield
1.34%
Annual payout
0.98
Next ex. div date
June 9, 27
Payout
61.92%
Div.growth, 5y
36.49%
Dividend growth streak
2 y
Div.rating
About the company
Ticker
BIM
ISIN
FR0013280286
Country
France
Sector (GICS)
Healthcare
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL, a rapid AST system; ETEST, a gradient method on culture media; BIOMERIEUX EPISEQ CS, a whole genome sequencing solution for epidemiologic monitoring; VIDAS, a specific marker of severe bacterial infections/sepsis; and Biomérieux vision suite, a software that provides information to support diagnosis and clinical decision making. It also provides culture media and associated instruments; ARGENE that provides PCR tests for diagnosing viral respiratory diseases; EMAG system and NUCLISENS extraction reagents for DNA and RNA extraction; GENE-UP and VERIFLOW for detection of microorganisms for the food industry; ETEST for manual measurement of minimum inhibitory concentration of an antibiotic; API and RAPIDEC CARBA NP for identification of bacteria and manual antimicrobial susceptibility testing; BIOBALL for quantitative microbiological quality control; CHEMUNEX, a microbiology instrument; ENDONEXT for detection of endotoxins; TEMPO for fluorescence counting of bacteria; and Hybiome, a CLIA technology, as well as lab consultancy service and training modules. The company was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. operates as a subsidiary of Institut Mérieux SA.

Frequently asked questions

What sector does Biomerieux SA (BIM) operate in?

Biomerieux SA belongs to the Healthcare sector and operates in the Diagnostics & Research industry.

What is Biomerieux SA (BIM) current stock price?

As of the latest data, Biomerieux SA stock price is €73.00, with a previous close of €73.00.

What is Biomerieux SA (BIM) current market capitalization?

Biomerieux SA market cap is approximately 8.59 billion.

What is Biomerieux SA (BIM) Earnings Per Share (EPS)?

The trailing EPS is €3.90, and the forward EPS is €4.66.

What is Biomerieux SA (BIM) Price-to-Earnings (P/E) ratio?

Biomerieux SA current P/E ratio is 18.72, with a forward P/E of 15.65.

What is Biomerieux SA (BIM) EBITDA?

Biomerieux SA EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 441.20 million.

Does Biomerieux SA (BIM) pay dividends?

Yes. Biomerieux SA pays annual dividends with an annualized yield of 1.34% and an estimated annual payout of €0.98 per share.

When is the next ex-dividend date for Biomerieux SA (BIM)?

The next ex-dividend date is scheduled for June 09, 2027.

When is Biomerieux SA (BIM) next earnings report?

Biomerieux SA is expected to release its next earnings report on June 30, 2026.

What is Biomerieux SA (BIM) beta (volatility) score?

Biomerieux SA has a beta of 0.570, indicating lower volatility than the overall market.